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Obesity is a chronic pathological condition and a risk factor for diabetes and 
cardiovascular disease. It has been demonstrated that adipose tissue functions not 
only as a fat storage depot but also as an endocrine organ. Omentin is a protein 
expressed and secreted in adipose tissue that increases insulin-stimulated glucose 
transport. To further elucidate omentin’s physiological function, its levels were 
measured by quantitative western blotting in plasma from 44 healthy nondiabetic 
volunteers (22 women, 22 men). Participants were organized into sibling pairs based 
on discordant BMI (3-12 Kg/m2). Lean subjects had significantly higher omentin 
levels than obese/overweight subjects (independent of sex), and significantly higher 
omentin levels were detected in women compared to men. Omentin levels were 
inversely correlated with BMI and positively correlated with HDL levels. These data 
suggest that omentin may play a physiological role in the pathogenesis of obesity-
dependent insulin resistance.   
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CHAPTER 1: BACKGROUND INFORMATION 
1 – Obesity 
1.1 - Definitions and assessments 
According to the World Health Organization (WHO), obesity is the 
accumulation of excessive body fat negatively affecting health. It was declared one of 
the top ten health risk conditions in the world, affecting about 300 million people 
worldwide (60 million adults in the United States alone; 1-5).  
As simple as the definition of obesity appears, establishing the best technique 
to measure obesity has been a matter of dispute. The most accurate techniques to 
assess body fat, such as hydrostatic weighing, absorptiometry, bioelectrical 
impedance and computed tomography are also the most technically challenging, 
demanding specialized training and equipment and, therefore, the most expensive. 
For these reasons, skinfold thicknesses and weight-and-height indexes have been 
adopted as substitute measurement methods in clinical and public health works (6). 
Skinfold thickness is a measurement of the thickness of the double layer of 
skin and subcutaneous tissue obtained with specialized calipers. This method can be 
used to estimate fatness and characterize its distribution. The main advantage of this 
measurement is the possibility to determine adiposity levels. However, this 
assessment has important limitations such as standardization and reproducibility of 
measurements. Because of these limitations, weight-and-height indexes are most 
commonly used worldwide as an assessment of obesity (6). 
 1
The body mass index (BMI, Kg/m2), a weight-and-height index, is the 
international measure of obesity. Subjects are categorized as healthy (BMI < 18 
Kg/m2), lean (BMI < 25 Kg/m2), obese (BMI ≥ 30.0 Kg/m2), or overweight (25 
Kg/m2 ≤ BMI < 30 Kg/m2). Increasing BMI values are correlated with an increased 
risk of morbidity and mortality. BMI information has the great advantage of being 
easy to obtain. However, as its main disadvantage, BMI is not always a measure of 
adiposity, if the excess weight is caused by muscularity. When used for obesity 
assessment in children and adolescents, it is necessary to correct BMI for sex and age, 
because growth and sex hormones affect weight/height and body fat distribution 
respectively (2, 6, 7, 8). 
Waist circumference and the ratio of waist circumference to hip circumference 
(waist-to-hip ratios) have also been used as an assessment of body fat distribution. 
Independent of body mass, increased localization of fat in the abdominal region is a 
risk factor for cardiovascular disease (CVD) and diabetes. Values of waist 
circumference higher than 102 cm (40.2") for men and 88 cm (34.6") for women are 
considered an increased risk for morbidity. Waist-to-hip ratios higher than 1 for men 
and 0.85 for women are also indicative of increased risk for the development of 






1.2 – Epidemiology of Obesity  
 Worldwide, more than one billion adults are overweight and about 300 million 
are obese. Obesity and overweight have increased dramatically in several countries. 
For example, in less than 10 years in China (1989 – 1997) the prevalence of 
overweight individuals doubled in women and tripled in men (1, 9).  
Based on BMI values, according to data from the National Health and 
Nutrition Examination Survey (NHANES III, 1999-2000), almost 65% of the 
American adult population is overweight. These data represent an increase from the 
already high incidence rate of 56% found in the previous assessment (NHANES III, 
1988-1994). The incidence of obesity in adults paralleled this tendency and increased 
from 23% to 31% during the same period of time (1, 6, 7, 9). 
Based on the BMI distributions from the NHANES II and III studies, Hill et al 
(2003) projected obesity and overweight incidence to 2008 (figure 1). They estimated 
that obesity would increase to 39% of the adult American population. The ratio 
between lean and obese individuals is represented in the axis y, and BMI distributions 
are shown in the axis x. The cut-off points for overweight (BMI = 25 Kg/m2) and 
obesity (BMI = 30 Kg/m2) are also shown (1).  
Interestingly, according to the NHANES III (1988-1994), the prevalence of 
obesity in American adults was higher in women than in men. A higher prevalence of 
overweight women was found in African-American (37%) and Mexican-American 
(33%) populations than in the Caucasian population (22.7%). This pattern was not 
observed for men (6, table 1). This difference in obesity prevalence between genders 
has been tentatively explained by the regulation of body fat distribution by sex 
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hormones. Usually, women have higher proportion of fat relative to total body weight 
than men. This characteristic is thought to be evolutionarily advantageous because of 
the metabolic burden of birth and care of children associated with women. However, 
the molecular and physiological role played by sex hormones in fat distribution is far 
from understood (10, 11). 
 
Race or ethnicity      Male (% obese)  Female (% obese) 
 
All U.S. adults   19.5    25.0 
Non-Hispanic white   19.9    22.7 
Non-Hispanic black   20.7    36.7 
Mexican American    20.6    33.3 
 
 
Table 1.  Obesity prevalence stratified by sex and race. Data from NHANES III 
(1988-1994); see figure 1 for details. Adapted from Galuska and Khan, 2001 (6).  
 
It has been observed that obesity is most prevalent for middle-age adults in 
developed countries. Surprisingly, in the United States, the highest incidence of 
weight gain has occurred for adults between 24 to 34 years. However, it is important 
to notice that the prevalence of obesity among children and adolescents in the United 
States from 1988 to 1994 increased in a 2-fold ratio compared with the previous 
decade. These data indicate that the number of overweight and obese individuals is 
increasing, but also, the age that an individual reaches overweight/obesity levels is 
decreasing. Combined, these data indicate that the deleterious health consequences of 
excessive body fat will affect an ever younger population (1, 6, 7, 9). 
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Due to the serious implications of obesity, its direct health care costs in the 
United States were approximately $70 billion (7% of the total health costs) in 2001. 
These figures are in agreement with the cost of obesity in other developed nations (2-
7% of the national health care costs in Australia, France and the Netherlands). 
However, this value did not account for the indirect costs related to loss of 
productivity and quality of life. In 2003, it was estimated that obesity accounted for 
5.5 to 7.8% of all health care expenditures, representing about 39.2 million lost work 
days per year in the United States (1,6). 
 
Figure 1.  Obesity prevalence continuously increases in American society. From 
1988-1994 to 1999-2000, a larger percentage of the population had higher BMI index, 
indicating increased body weight. Values for obesity were estimated to reach 39% of 
the total population in only 4 more years. Adapted from Hill et al, 2003.    
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1.3 – Causes of Obesity  
Obesity is the result of an imbalance between energy intake and expenditure. 
As in most human pathological conditions, genetic and environmental conditions play 
a role in its pathogenesis. In order to maintain a stable and healthy body weight, 
according to the equation of energy balance (energy intake = energy output + stored 
energy), the intake and expenditure of energy should be equivalent. However, due to 
increasingly sedentary life styles and diet changes, a positive energy balance has been 
created in the majority of developed countries (12, 13). 
Energy intake is directly influenced by environmental conditions. Due to the 
development of food technologies like processing, storage and distribution, the food 
industry can largely influence the type and amount of food consumed. Both package 
and portion sizes of foods have increased. It has been shown that the amount of food 
provided can affect energy intake. Moreover, food availability in developed countries 
has increased in the past 20 years. The combined effect of more and higher caloric 
food with less exercise have fueled the increase in body weight observed in 
developed societies (13, 14).  
Habits and beliefs play a role in food choices, such as meal times, food 
preferences and portion sizes. In industrialized countries, it has become easier to 
choose fast food instead of home prepared foods. Social context also influences the 
selection and consumption of food based on the daily rhythm of life. Consequently, it 
has been seen an increased propensity to eat without physiological needs (13). 
Food sensory properties influence pleasure while eating and, therefore, food 
selection. It is known that fat is a main component responsible for taste in food. 
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Consequently, fat combined with sugar and salt improves sensory properties and 
contributes to selection of food with high fat content (13). 
Energy output can be divided into basal metabolic rate, thermic effect of food, 
and energy expended by physical activity. These three classes represent respectively 
about 60-70%, 10%, and 20-30% of daily energy expenditure. The most modifiable 
of these factors is physical activity. However, several factors affect physical activity 
frequency, such as age, gender, socioeconomic status, and education. Unfortunately, a 
sedentary life style has become usual in developed countries due to technological 
advances (13).  
Like environmental factors, genetic factors contribute to obesity. During 
human evolution, energy storage as fat was an important survival adaptation. 
However, with increased food availability and decreased physical activity, these 
"thrifty" genes will influence the expression of obesity, a survival disadvantage. 
Several population studies estimated that the heritability of body mass or body fat can 
be derived from genetic information in the range of 24-70%. This effect is considered 
polygenic and may also depend on sex and age (2, 13, 15, 16, figure 2). 
 Obesity can also be a component of diseases which mostly affect the 
endocrine system. For example, Cushing’s disease, polycystic ovary syndrome, 
hypothyroidism, hypogonadism, and growth hormone deficiencies are diseases 
associated with obesity. Medications, especially antidepressants, glucocorticoids, 





Figure 2. Genetic background modulates obesity, but the effect can be overcome by 
controlling energy balance. Normal individuals have small variations on BMI upon 
changes in energy intake or expenditure. The changes in BMI are much more intense 
for genetically susceptible individuals. Observe the widening and “shift to right” for 
increase in energy intake and/or decreased expenditure in the graph. Also, rare single 
gene mutations can condition for extremely high BMI values. Adapted from 






1.4 – Health Effects of Obesity  
Obesity is a chronic pathological condition and a risk factor for type 2 
diabetes and cardiovascular disease (CVD). Overweight or obese people have a 
greater probability than normal-weight people of developing metabolic syndrome, a 
condition characterized by high blood pressure, insulin resistance, and dyslipidemias 
(high levels of total cholesterol, triglycerides and LDL and low levels of HDL). It is 
estimated that 20-25% of adults in the United States have acquired metabolic 
syndrome (17 – 24).  
Obesity during pregnancy may cause congenital malformations, such as neural 
tube effects, hypertension and gestational diabetes. In addition to these conditions, 
obesity also increases the risk of polycystic ovary disease, ischemic stroke, sleep 
apnea, gallbladder disease, gastroesophageal reflux, osteoarthritis, colon cancer, 
postmenopausal breast cancer, and psychological disorders, such as depression (6). 
According to the Rand Institute, obesity is a higher risk for chronic diseases 
than living in poverty, smoking or drinking. Approximately 300,000 people die every 







1.5 – Treatment and Prevention of Obesity  
 Any intervention aimed at treating obesity should focus on how to restore 
balance to energy intake and energy expenditure. In a simplified form, these 
interventions could be divided into three classes: diet modifications, physical activity 
improvement, and clinical interventions (6, 12, 13). 
 The main objective of diet modification is to reduce energy intake. It has been 
shown that overweight subjects on a low-calorie diet (800-1500 Kcal / day) reduced 
body weight by an average of 8% over 3-12 months. According to several studies, 
this intervention also works for children and adolescents. A great variety of weight 
loss diets have been offered commercially. Although some of these popular diets 
work very well in a short term, they do not offer a nutritionally balanced diet. 
Therefore, the potential to lose weight but to develop other health problems 
secondary to poor diet remains (6, 12, 13).  
 Increased physical activity can be used to balance energy expenditure by 
increasing the amount of energy the body uses. It is very efficacious because it 
increases body energy use not only during physical exercise, but physical activity also 
increases the basal metabolic rate, increasing energy use throughout the day. Physical 
exercise can be used for weight loss in adults and children, although, in both cases 
medical supervision is always indicated. Physical activity also offers several other 
benefits (mental and physical) than weight loss. It is well documented that it increases 
self-confidence, improves mood, decreases cardio-vascular disease (independent of 
weight loss) and the risk of drug use. But physical activity alone without diet changes 
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has a smaller effect on weight loss than that obtained with both interventions (6, 12, 
13).   
Clinical interventions include pharmacological and surgical therapies. 
Pharmacological therapies can be divided in three groups: to reduce food intake by 
increasing the feeling of satiety; to affect metabolism by inhibiting intestinal 
digestion and absorption of fat; and to increase energy expenditure by causing weight 
loss. According to recent randomized controlled trials, pharmacological treatments 
used along with life style changes for 6-12 months reduced body weight in a range of 
2-10 Kg in obese people. However, due to the side effects of those drugs, they are 
only recommended for people who have a higher health risk secondary to obesity. On 
the other hand, surgical interventions are used to reduce food intake by changing the 
gastrointestinal capacity. Although gastric bypass results in considerable weight loss, 
this intervention is indicated only for people who were unsuccessful in using the 
interventions described above (6, 12, 13). 
In addition to the strategies focused on balancing energy intake and 
expenditure, there is a need of a stronger nutritional knowledge for medical 
practitioners. Currently, the majority of medical schools do not offer this kind of 
training. Consequently, the practitioners do not have the skills to advise and guide 
their patients though life-style changes. On a more broad scale, health and nutritional 
education of the general public should be a powerful way of changing population life-
style. A good example is the nonsmoking campaign. In the past two decades, the 
number of smokers has decreased significantly; from 50% of the adult population in 
the 50’s to 25% in the beginning of the 90’s and with some studies indicating a 
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reduction to 16% of adult smokers in some population cohorts. In summary, obesity 
is an epidemic health problem that needs to be combated vigorously without loss of 
time in order to counteract the already present health consequences (13, 25).  
 
2. Adipose Tissue as an Endocrine Organ 
Fat tissue has been traditionally viewed as an energy storage depot composed 
of fat storing cells (adipocytes) embedded in a simple matrix of connective tissue 
with stromovascular and immune cells (4, 11).  
Recently, this traditional view of fat cells as simply energy storage has been 
challenged. In 1987, it was found that sex steroids have their major site of production 
in adipose tissue. Soon thereafter, in 1994, the identification of leptin contributed for 
the establishment of the adipose tissue as an endocrine organ. Currently, with the 
identification of a number of pro-hormones, hormones, enzymes and cytokines 
expressed and released from adipose tissue, it is clear that this tissue functions not 
only as a passive fat storage depot but also as an endocrine organ (26 – 31, table 2).  
Cytokine is a general name for small secreted proteins that are involved in a 
plethora of processes like immunity, inflammation, and hematopoiesis. Generally, 
they act over short time at very low concentration. Their mechanism of action 
involves modulation of gene expression and consequent metabolic alterations. Their 
actions are mediated by binding with specific membrane receptors which use 
intracellular second messenger cascades. Interestingly, the production and release of 
cytokines also obey a cascading order, with one cytokine stimulating its target cells to 
make additional cytokines. These compounds can also act synergistically (two or 
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more cytokines acting together) or antagonistically (cytokines causing opposing 
activities). Therefore, cytokines form an extremely interdependent signaling network 
with the final metabolic effect being the combined interplay of many different 
actions. Cytokines expressed and secreted in adipose tissue receive the particular 
name of adipocytokines. They may act on the cells that secrete them (autocrine 
action), on proximal cells (paracrine action), or in a systemic level (endocrine action). 
Therefore, through this integration of other organs, adipose tissue plays a role in the 
regulation of energy balance, neuroendocrine function, and immunological responses 
(26, 27). 
 Adipose tissue can be divided in two types: white and brown. Brown adipose 
tissue is generally found in small amounts in adults and contributes to resting 
metabolic rate with its thermogenic capacity. On the other hand, white adipose tissue 
can be broadly classified as visceral (organ fat) and subcutaneous (under the skin). 
Omental visceral fat is more metabolically active than subcutaneous adipose tissue. It 
also contains large insulin-resistant adipocytes, when compared with the smaller more 
insulin-sensitive adipocytes found in subcutaneous fat (4, 32, 33).  
It is known that increased visceral adiposity promotes increased levels of 
circulating non-esterified fatty acid (NEFA). The resulting increased NEFA levels 
inhibit insulin clearance by the liver causing increased plasma levels of insulin 
(hyperinsulinemia), and inhibition of insulin action on insulin-sensitive tissues 
(insulin resistance) such as liver and muscles. Some studies have also shown that 
increased release of fatty acids from visceral fat cells to the portal venous system 
results in increased release of both glucose and insulin. Taken together, these results 
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suggest that increased NEFA circulating levels cause a significant inhibition of 
glucose transport activity. Consequently, obesity, especially in the visceral region, is 
strongly associated with insulin resistance, hyperglycemia, dyslipidemia and 
hypertension, leading to cardiovascular disease (4, 5, 26).  
The Honolulu Heart Study showed that the risk of coronary artery disease was 
equivalent in both non-obese group with predominant visceral fat distribution and the 
obese group with equivalent visceral fat distribution. On the contrary, the obese group 
with subcutaneous obesity had only a slightly higher risk than the non-obese group 
with predominantly subcutaneous fat distribution. The presence of predominantly 
visceral fat, even in the absence of body obesity, is sufficient to increase the risk of 
cardiovascular disease. Interestingly, obesity and its associated morbidities (metabolic 
syndrome) are also induced by adipose tissue deficit. Therefore, both excess and 
deficit of adipose tissue have negative impacts on health (4).    
Cancers of colon, breast, endometrium, kidney, and esophagus have also been 
associated with obesity. An imbalance between cell proliferation, differentiation, and 
apoptosis can be caused by alterations in the metabolism of hormones, such as 
estrogen, insulin, and insulin-like growth factor. Therefore, the growth of adipose 
tissue observed in obesity and consequently the increased release of growth factors 
may facilitate cancer development (26).        
Among the several endocrine hormones expressed and secreted by adipose 




Function      Protein secreted by adipocytes 
 
Cytokines and cytokine-related protein   Leptin  
        TNF∝ 
        IL-6 
Other immune-related proteins    MCP-1 
Proteins involved in the fibrinolytic system   PAI-1 
        Tissue factor 
Complement and complement-related proteins  Adipsin 
        Complement factor B 
        ASP 
        Adiponectin 
Lipids and proteins for lipid metabolism or transport Lipoprotein lipase (LPL) 
        CETP 
        Apolipoprotein E 
        NEFAs 
Enzymes involved in steroid metabolism   Cytochrome P450 
        17βHSD 
        11βHSD1 
Proteins of the RAS      AGT 
Other proteins       Resistin  
         
 
Table 2. Partial list of proteins secreted by adipocytes with predominantly endocrine 
functions. Not all of these proteins are adipocytokines because they were first 
characterized in other body organs and/or have their main function in other body 
systems. However, they evidence the metabolically active state of the adipose tissue. 





2.1 – Leptin 
Leptin, the product of the obesity gene ob/ob, was discovered in 1994 by 
Friedman and colleagues. Leptin, also called OB protein, is a 16-kDa glycosylated 
protein of 167 amino acid residues produced predominantly by white adipose tissue. 
Higher levels of leptin mRNA have been detected in subcutaneous than in visceral 
adipose tissue, a finding that correlates with higher leptin release from subcutaneous 
adipose tissue. Leptin expression in low levels was also found in the hypothalamus, 
pituitary placenta, skeletal muscle, and gastric and mammary epithelia (27, 31, 34, 
35).  
Leptin has been characterized as an important regulator of food intake by 
exchanging information from the periphery to the central nervous system (CNS). Fat 
mass is directly correlated with leptin circulating levels, consequently, increased 
amount of energy stored in adipose tissue increases leptin circulating levels. As a 
result, decreased hunger, increased sympathetic activity, and increased thermogenesis 
are observed. Therefore, leptin is involved in the regulation of appetite, food intake 
and energy expenditure. In addition to that, it has been demonstrated that leptin is also 
correlated with regulation of sexual maturation, fertility, hematopoiesis, and bone 
development (4, 26, 29, 34, figure 3).  
Initial studies showed that leptin knockout mice became hyperphagic and 
obese when allowed to eat ad libidum. This phenotype was rescued by administration 
of leptin, which promoted reduced food intake and increased metabolic rate. These 
studies suggested that leptin could be used as a pharmacological intervention to treat 
obesity. However, administration of leptin to obese individuals failed to reduce 
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adiposity; since they already had high circulating leptin levels, suggesting a state of 
leptin resistance. The mechanism for leptin resistance is not clear yet, but restricted 
transport of leptin to the brain, and/or a reduced hypothalamic leptin signaling 
(impaired intracellular signal transduction) has been proposed to play a role (15, 34).           
Interestingly, it has also been indicated that women have higher leptin levels than 
men (36, 37, 38, 40). Additionally, other studies also indicated that leptin correlates 
positively with BMI (body mass index), and HOMA (homeostasis model assessment 
of insulin resistance). HOMA (defined as the product of fasting plasma insulin and 
glucose divided by 22.5) is a tool to estimate insulin sensitivity from a single sample 
(36, 38, 39, 40).  
 Several hormones, such as, insulin, glucocorticoids, estrogens, and tumor 
necrosis factor α (TNF-α) stimulate leptin production. The opposite effect is 










Figure 3. Leptin levels are directly proportional to body fat. It acts as an appetite and 
metabolism regulator balancing body’s fat content. Adapted from Marx, 2003.  
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2.2 – Adiponectin 
 Adiponectin, also called apM1, Acrp30, adipoQ, and GBP28, was 
simultaneously described by four different groups in 1995 and 1996 (26). This 30-
kDa polypeptide with 244 amino acids is expressed and secreted exclusively in white 
adipose tissue (26, 34). Many of its characteristics are the opposite of leptin, i.e., it 
has been shown that adiponectin expression and secretion are higher in visceral than 
in subcutaneous adipose tissue. Also its gene expression is decreased by obesity, 
glucocorticoids, beta-adrenergic agonists, and TNF-α and increased by leanness, 
activation of the nuclear receptor PPAR-γ (peroxisome proliferator-activated receptor 
gamma), and cold exposure (26, 28, 42, 43). 
Plasma adiponectin circulates at high levels in human bloodstream (range 0.5 
to 30 µg/mL). Compared with leptin and insulin, adiponectin is found in about 1000-
fold higher than those hormones. Adiponectin is considered the most abundant 
adipose tissue protein, accounting for about 0.01% of total human plasma protein (26, 
29, 42).   
 It has been established that low adiponectin levels are associated with obesity 
and several components of the metabolic syndrome, such as, hyperlipidemia, low 
HDL levels, and insulin resistance/type 2 diabetes (26, 34, 42).   
Several studies have indicated that adiponectin acts as an insulin-sensitizing 
hormone (26, 29, 34, 42, 44). For example, adiponectin administration to rodents 
showed an increase in glucose uptake and fat oxidation in muscle, a reduction in fatty 
acid uptake and hepatic glucose production in liver, improving insulin-sensitivity. In 
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addition, thiazolidinediones (TZD drugs), used to enhance insulin sensitivity, 
increased plasma adiponectin and mRNA levels in mice (34, 44, figure 4).  
In support of those findings, a negative correlation between human plasma 
adiponectin levels and body mass index (BMI), homeostasis model assessment of 
insulin resistance (HOMA), body fat mass, insulin resistance, and insulin levels was 
described (34, 39, 42, 45, 46, 47).  
 Adiponectin is also considered to protect against cardiovascular disease. It has 
been hypothesized that low adiponectin levels correlate with the development of 
atherosclerosis and cardiovascular disease, a hypothesis corroborated by a study 
showing that adiponectin acts as an anti-atherosclerotic protein on endothelial cells. 
Moreover, adiponectin is positively correlated with HDL concentrations, and 
negatively correlated with LDL, and triglyceride levels (45, 46, 48).    
 It has been reported that adiponectin levels are higher in lean than in obese 
subjects (36, 42, 46, 49). Adiponectin circulating concentrations are also higher in 
females than in males, possibly explaining in part the lower risk of cardiovascular 
disease found in women (29, 36, 37, 42, 46, 49, 50). Moreover, in contrast to 
decreased adiponectin levels in obese subjects, adiponectin concentrations were 








Figure 4. Proposed model for adiponectin secretion and action. In adipocytes, leptin 
deficiency/resistance and/or caloric excess reduce adiponectin expression and 
secretion. Conversely, activation of nuclear receptor PPAR-γ increases adiponectin 
synthesis, which increases fatty acids (FFAs) transport and oxidation in skeletal 
muscle, as well as, glucose utilization. The combined effect of adiponectin is a 
reduction in circulating lipids, improved glucose tolerance and insulin sensitivity. 
Adapted from Saltiel, 2001.    
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2.3 – Resistin 
 Resistin, named after “resistance to insulin” and also called “adipose-tissue-
specific secretory factor” and “FIZZ3”, is a 12-kDa polypeptide with 114 amino 
acids, which was identified in 2001 by Steppan and colleagues (26, 34).  
Initial studies indicated that resistin is expressed and secreted 15 times higher 
in visceral than in subcutaneous adipose tissue in rodents (26). 
It has been shown that resistin is correlated with obesity-related insulin 
resistance (26, 51, 54). Resistin administration in rodents induced insulin resistance, 
impaired glucose tolerance and insulin action. Interestingly, neutralization of resistin 
by anti-resistin antibodies reduced glucose levels and improved insulin sensitivity 
(26, 29, 31, 34).        
Moreover, some studies have indicated that resistin is down regulated by the 
antidiabetic drug rosaglitazone (a TZD compound used to enhance insulin sensitivity, 
26, 29, 34, 52, figure 5).     
In support of those findings, it has been found that plasma resistin levels are 
higher in obese than in lean subjects (36, 53). In an analysis of subgroups, it was 
shown higher levels of resistin in obese versus lean females, but without difference 
between obese and lean males (53). In addition, higher resistin levels were found in 
women than in men (36, 37, 53). Moreover, resistin levels were also correlated 
positively with body mass index (BMI), homeostasis model assessment of insulin 





Figure 5. Proposed model for resistin secretion and actions. Higher leptin levels 
decrease food intake and increase energy expenditure, resulting in negative energy 
balance and lower resistin levels. This decreases insulin-resistance, benefiting 
diabetes control. Adapted from Shuldiner et al, 2001.    
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TABLE 3 – Comparison of metabolic characteristics between adiponectin, leptin, and 
resistin.   
 
Characteristics Adiponectin Leptin Resistin 
Lean x Obese  Higher levels in 
lean subjects 
Higher levels in 
obese subjects 
Higher levels in 
obese subjects 
 
Lean x Obese (Women) Higher levels in 
lean subjects 
Higher levels in 
lean subjects 
Higher levels in 
lean subjects 
 
Lean x Obese (Men) Higher levels in 
lean subjects 





Females x Males Higher levels in 
females 
Higher levels in 
females 
Higher levels in 
females 
 
Correlation w/ BMI − 
 
+ + 


















































2.4 – Omentin 
 Omentin is a 35-kDa protein with 313 amino acids, named after its preferred 
expression in omental (visceral) rather than subcutaneous fat tissue. It was cloned and 
sequenced in 2002 at the Division of Endocrinology, Diabetes and Nutrition 
(University of Maryland Baltimore).  
Preliminary data indicated that omentin can be detected in human serum, and 
is positively correlated with insulin signal transduction and insulin-stimulated glucose 
transport in 3T3-L1 adipocytes and isolated human adipocytes. In addition, omentin 
secretion was positively regulated by dexamethasone and thiazolidininedione (insulin 
sensitizers). 
These preliminary data suggest that omentin may play a positive role in 
maintaining insulin sensitivity; consequently omentin levels may be decreased in 
obesity-related insulin resistance.  
In consequence, these preliminary findings raise the following hypotheses: 
(a) omentin levels are higher in lean than obese individuals; 
(b) omentin levels are higher in female lean than female obese individuals; 
(c) omentin levels are higher in male lean than male obese individuals; 
(d) omentin levels are negatively correlated with BMI; 
(e) omentin levels are negatively correlated with HOMA; 
(f) omentin levels are negatively correlated with triglyceride levels; 
(g) omentin levels are negatively correlated with total cholesterol levels; 
(h) omentin levels are negatively correlated with LDL levels; 
(i) omentin levels are positively correlated with HDL; 
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(j) omentin levels are negatively correlated with fasting insulin levels; 
(k) omentin levels are negatively correlated with fasting glucose levels; 
(l) omentin levels are negatively correlated with blood pressure. 
 
 In order to test these hypotheses, this study was designed to (i) compare 
plasma omentin levels in lean and obese/overweight subjects; (ii) and to investigate 
the relationships between plasma omentin levels and several metabolic indices such 
as body mass index (BMI), insulin resistance index (HOMA), lipid profile 
(triglycerides, total cholesterol, HDL, and LDL levels), fasting insulin and glucose 















CHAPTER 2: RESEARCH DESIGN AND METHODS 
2.1 – Subjects 
Subjects included 44 healthy nondiabetic volunteers (22 women and 22 men) 
who participated in the Amish Family Diabetes Study (AFDS) conducted by the 
Division of Endocrinology, Diabetes and Nutrition, University of Maryland at 
Baltimore. The study protocol was approved by the Institutional Review Boards for 
Human Subject Research at University of Maryland (both from College Park and 
Baltimore) and written informed consent was obtained from all subjects. Participants 
were organized in sibling pairs based on sex (same gender), age (1-5 years of 
interval) and BMI (discordant pairs; 3-12 Kg/m2) (table 4). Subjects of the same 
family were paired, i.e., sisters with sisters, and brothers with brothers. The sibling 
pairs were divided in two groups: (a) lean (BMI<25Kg/m2); or (b) overweight 









Table 4. Participants were organized in sibling pairs (relatives). The division was 
based on sex (same gender), age (1-5 years of interval) and BMI (discordant pairs; 3-
12 Kg/m2).  
Pair Subject ID Gender BMI Age Subject ID Gender BMI Age 
1 577 F 21.5 46 1472 F 26.3 45 
2 7280 F 20.3 30 6601 F 33.1 29 
3 4317 F 24 30 4316 F 33.5 33 
4 7243 F 23.1 25 7241 F 28.9 26 
5 1491 F 21.8 27 1493 F 25.5 24 
6 7062 F 21.2 20 7063 F 27.6 21 
7 7122 F 19.8 70 7043 F 25.2 71 
8 7297 F 21.5 25 7296 F 26.8 27 
9 593 F 22.9 59 4314 F 28.7 56 
10 7049 F 17.5 39 7077 F 25.8 42 
11 503 F 22.9 50 478 F 33.6 47 
12 1414 M 17.0 43 8027 M 27.8 48 
13 7279 M 23.0 57 7271 M 31.0 56 
14 7254 M 21.8 58 1295 M 26.6 57 
15 520 M 19.8 42 526 M 27.9 44 
16 7099 M 21.5 34 7098 M 29.4 39 
17 611 M 22.9 44 627 M 30.2 39 
18 6554 M 24.8 38 621 M 30.55 35 
19 1333 M 23.6 30 1329 M 31.5 33 
20 7086 M 24.9 65 7078 M 30.1 61 
21 1314 M 23.4 32 1349 M 27.6 38 







2.2 – Clinical Characteristics 
The clinical characteristics of the participants of the study were contributed by 
Dr. Alan Shuldiner (Professor & Head, Division of Endocrinology, Diabetes and 
Nutrition – UMB).    
Blood was drawn after an overnight fast, and plasma was separated by 
centrifugation using standard procedures. Aliquots were prepared for determination of 
glucose, insulin, triglycerides, total cholesterol and high density lipoprotein (HDL) 
levels; and frozen at − 80°C for additional assays (omentin). The researchers also 
measured the height, weight, and blood pressure of the subjects.  
Blood glucose was measured using a glucose analyzer (Beckman). Insulin 
levels were determined by enzyme-linked immunosorbent assay RIA (Linco 
Research, Inc.). Homeostasis model of assessment (HOMA) score was calculated as 
fasting insulin (µU/mL) x fasting glucose (mM) divided by 22.5 (55). 
Total cholesterol, HDL cholesterol and triglycerides were determined 
enzymatically using commercial kits on a Hitachi 747 auto analyzer (Roche). Low 
density lipoprotein (LDL) levels were calculated using the Friedewald Equation, 
where all concentrations are given in mmol/L and the quotient ([TG]/2.2) is used as 
an estimate of VLDL-cholesterol concentration (56). 
 




2.3 – Quantification of Plasma Omentin Levels 
2.3.1 – Quantification of Purified Omentin Levels (Step 1)  
 Purified omentin, obtained from Dr. Gong (Division of Endocrinology, 
Diabetes and Nutrition – UMB), was used as a standard for the quantification of 
plasma omentin levels in the samples.   
The purified omentin concentration was quantified by SDS-PAGE (sodium 
dodecyl sulphate - polyacrylamide gel electrophoresis) and Sypro Ruby fluorescent 
protein stain (Bio-Rad) using purified bovine serum albumin (BSA) as a standard. 
Five BSA purified solutions (6.25; 12.5; 18.75; 25.0; and 37.5 µg/mL) and a solution 
prepared from purified omentin (6.6 times more concentrated than the original 
purified omentin) were denatured with 0.002% DTT (dithiothreitol) in Laemnli 
Sample Buffer for 3 minutes at 95°C (Bio-Rad). After this treatment, the standards 
and purified omentin were electrophoresed in duplicate on 10% SDS-PAGE gels 
(Criterion Pre- Cast Bio-Rad) for 30 and 60 minutes respectively at 125 and 150 
Volts. The gel was placed into a foil-covered with 50 mL of Sypro Ruby Stain 
solution (Bio-Rad), and agitated in a shaker at room temperature for 12 hours. After 
that, the gel was washed with a 10% methanol/ 7% acetic acid solution twice for 10 
and 20 minutes respectively. Fluorescent band intensities were visualized by 305 nm 
UV light and quantified on a Fluorchem 8000 chemilumenescent/fluorescent imager 
(Alpha Innotech) (figure 6). 
A standard curve was constructed using the log transformed BSA 
concentrations (x-axis) versus the band intensities (y-axis) (figure 7, 57). 
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2.3.2 – Quantification of Standard Plasma Samples (Step 2) 
 Due to the difficulty of over expressing and purifying omentin, some plasma 
samples were quantified using purified omentin as a standard. These quantified 
plasma samples were used as “standard plasma” to quantify the samples from the 
subjects.     
 Standard plasma omentin levels were measured by an immunoblotting 
analysis (quantitative western blotting) using purified omentin as a control. Plasma 
samples and three purified omentin solutions (0.1; 0.15; and 0.2 µg/mL) were 
denatured with 0.002% DTT in Laemnli Sample Buffer for 3 minutes at 95°C (Bio-
Rad). Then, the “standard plasma” samples and purified omentin were 
electrophoresed in triplicate on 10% SDS-PAGE gels (Criterion Pre- Cast Bio-Rad) 
for 30 and 60 minutes respectively at 125 and 150 Volts. After that, the proteins were 
transferred to Immobilon-PVDF membrane (Millipore) by using the Bio-Rad 
transfer system for 50 minutes at 100 Volts.  The membranes were removed from the 
transfer apparatus and the nonspecific binding sites were blocked for 30 minutes at 
room temperature with starting block solution (Pierce) plus 0.1% Tween 20 (also 
called Polysorbate 20, Pierce). In sequence, the membranes were rinsed twice for 5 
minutes with TTBS (Tween-Tris Buffered Saline: 0.1% Tween-20 in 100 mM Tris-
CL [pH 7.5], 0.9% NaCl). Incubation in primary antibodies 3G1B3, a human omentin 
specific monoclonal antibody obtained from Dr. Gong (Professor, Division of 
Endocrinology, Diabetes and Nutrition – UMB), was carried out for 1.5 h at room 
temperature in a shaker. Antibodies were diluted 1:24 in starting block solution plus 
0.1% Tween 20 (Pierce). Horseradish peroxidase-conjugated anti-mouse secondary 
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antibodies (KPL) were diluted 1:30,000 in starting block solution plus 0.1% Tween 
20 (Pierce) and incubated with the blots for 40 minutes at room temperature in a 
shaker. After incubation with primary and secondary antibodies, membranes were 
washed three times for 10 minutes with TTBS. Immunoreactive bands were 
visualized and quantified by chemiluminescent detection with the Femto-West kit 
(Pierce) on a Fluorchem 8000 chemilumenescent/fluorescent imager (Alpha 
Innotech) (figure 8). 
A standard curve was constructed using the log transformed purified omentin 
concentrations (x-axis) versus the optical densities (y-axis) (figure 9). 
 
2.3.3 – Quantification of Plasma Samples (Step 3) 
 Plasma omentin levels were measured by quantitative western blotting using 
“plasma standards” as a control. Plasma samples from the subjects and previously 
quantified “plasma standard” solutions (1.11, 1.66, and 2.21 µg/mL) were denatured 
in 0.002% DTT in Laemnli Sample Buffer for 3 minutes at 95°C (Bio-Rad). In 
sequence, the “plasma standard” solutions and plasma samples were electrophoresed 
in triplicate on 10% SDS-PAGE gels (Criterion Pre- Cast Bio-Rad) for 30 and 60 
minutes respectively at 125 and 150 Volts. After that, the same procedure used for the 
quantification of the “plasma standards” was followed for the subjects’ samples 
(figure 10).  
A standard curve was constructed using the log transformed “standard 




Figure 6. Quantification of purified omentin levels using BSA standards. Five 
concentrations of BSA (62.5; 125; 187.5; 250; and 375 µg/lane, marked S1 through 
S5, respectively) and omentin (marked Om) were loaded in duplicate on 10% SDS-
PAGE gel. Optical densities were measured on Fluorochem 8000 imager. The arrows 
indicate BSA and omentin bands.    
 33
 























Figure 7. Standard curve obtained for the quantification of purified omentin levels 
using BSA standards. The standard curve was obtained by plotting the log-transform 
of five BSA concentrations (6.25; 12.5; 18.75; 25.0; and 37.5 µg/mL) versus optical 
density (•). The purified omentin concentration (9 µg/mL) was obtained from this 







Figure 8. Quantification of plasma omentin levels (“standard plasmas”) using 
purified omentin. Plasma samples from human subjects (marked I through III) were 
run in triplicate on SDS-PAGE gel. On the same gel, three concentrations (1.25, 2.5, 
5 µg/lane, marked O1 through O3, respectively) of purified omentin were run in 


































Figure 9. Standard curve constructed for the quantification of “standard plasmas” 
using purified omentin as a control. The standard curve was obtained by plotting the 
log-transform of purified omentin concentrations versus their optical densities (•). 
Omentin concentrations in plasma were extrapolated from this standard curve. 
Results indicated values of 1.02, 1.07, and 1.22 µg/mL for standard plasmas I, II, and 







Figure 10. Quantification of plasma omentin levels using plasma samples of known 
concentrations (“standard plasmas”). Plasma samples from human subjects (marked 
A through E) were run in triplicate on SDS-PAGE gel. On the same gel, triplicates of 
“standard plasmas” previously quantified in relation to purified omentin (marked I 
through III) were also included. Optical densities were measured on Fluorochem 8000 































Figure 11. Standard curve obtained for the quantification of plasma omentin levels 
using “standard plasmas” as a control. The standard curve was constructed by plotting 
the log-transform of known omentin concentrations (“standard plasmas”) versus their 
optical densities (•). The concentrations of omentin in subjects’ plasma were 
extrapolated to the levels of omentin in plasma standards. The values indicated 
omentin concentrations of 0.77 ± 0.02, 3.08 ± 0.10, 0.82 ± 0.01, 0.71 ± 0.02, 0.45 ± 
0.02 µg/mL for subjects A to E, respectively (•).  
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2.4 – Statistical Analysis 
 Data are expressed as means ± S.E. Statistical analysis was performed using 
either paired Student t-test to investigate the differences in plasma omentin, insulin, 
glucose, triglycerides, total cholesterol, HDL, and LDL levels between lean and 
overweight/obese sibling pairs, or unpaired student t-test to verify the differences in 
omentin concentrations between males and females. Data were tested for normality of 
distribution by the Shapiro-Wilk test. In consequence, HOMA, plasma omentin, 
triglyceride, and insulin levels were log transformed to obtain a normal distribution. 
Pearson correlation coefficients were calculated to evaluate the relationship of plasma 
omentin concentrations with demographic and metabolic characteristics (age, BMI, 
HOMA, HDL, LDL, total cholesterol, triglycerides, fasting insulin, fasting glucose 










CHAPTER 3: EXPERIMENTAL RESULTS 
Metabolic and demographic characteristics of the subjects are presented in 
Table 5.  
 The mean fasting glucose levels were higher in overweight/obese subjects 
than in lean subjects. However, those values were in the normal non-diabetic range 
(<120 mg/dL) (table 5).  
 Fasting insulin levels and HOMA score (assessment of insulin resistance) 
were significantly lower in lean subjects (8.8 ± 0.4 µU/mL; 1.9 ± 0.1, n = 22) 
compared with overweight/obese subjects (13.4 ± 1.1 µU/mL; 3.0 ± 0.3; n = 22; P = 
0.001 for both variables, paired Student t-test, table 5).     
 HDL levels were significantly lower in overweight/obese subjects (41.9 ± 1.7 
mmol/L, n = 21) than in lean subjects (55.3 ± 2.6 mmol/L, n = 21, P < 0.0001, paired 
Student t-test, table 5).   
 Systolic and diastolic blood pressure were significantly higher in 
overweight/obese subjects (125.5 ± 3.1 mmHg; 82.1 ± 2.1 mmHg, n = 22) than in 
lean subjects (111.9 ± 3.7 mmHg; 74.8 ± 1.8 mmHg; n = 22; P < 0.05 for both 
variables, paired Student t-test, table  5).    
 Plasma omentin levels were significantly higher in lean subjects (1.1 ± 0.1 
µg/mL, n = 22) than in overweight/obese subjects (1.04 ± 0.02 µg/mL, n = 22, P = 
0.02, paired Student t-test) (figure 12 A, and B). 
The same pattern was found among women. Plasma omentin levels were 
found significantly higher in the lean group (1.25 ± 0.09 µg/mL, n = 11) than in the 
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overweight/obese group (1.08 ± 0.03 µg/mL, n = 11, P = 0.03, paired Student t-test, 
figure 13 A, and B). 
Interestingly, plasma omentin concentrations were not significantly different 
between lean males and overweight/obese males (1.03 ± 0.03 µg/mL, 1.01 ± 0.03 
µg/mL, respectively, n = 11, P = 0.39, paired Student t-test, figure 14, A and B). 
Like adiponectin, resistin and leptin, omentin levels were significantly higher 
in women compared with men (1.16 ± 0.05 µg/mL vs. 1.02 ± 0.02 µg/mL, n = 44, P = 
0.01, unpaired Student t-test, figure 15). 
Although age, total cholesterol, triglycerides, LDL, fasting glucose, fasting 
insulin, and HOMA were not significantly correlated with plasma omentin levels 
(Table 5), plasma omentin levels were significant negatively correlated with BMI  
(Pearson correlation coefficient, r = −0.39, r2 = 0.15, P = 0.0088, n = 44, 22 women, 
22 men, figure 16 A) . 
These data also indicated a significant positive correlation between omentin 
and HDL levels (Pearson correlation coefficient, r = 0.41, r2 = 0.16, P = 0.0078, n = 









TABLE 5 – Demographic and clinical characteristics of the subjects divided in lean 
and obese/overweight groups. Data are means ± S.E. P values are for the differences 
between the two groups by paired Student t-test.  
 
Characteristics Lean Obese/Overweight P 
n 22 22  
Sex (males/females) 11/11 11/11  
Age (years)   42 ± 3   43 ± 3 NS 
BMI (Kg/m2)   21.8 ± 0.4   29.0 ± 0.5 <0.0001 
Fasting Insulin (µU/mL)     8.8 ± 0.4   13.4 ± 1.1 0.001 
Fasting Glucose (mM)     4.9 ± 0.1     5.0 ± 0.1 NS 
HOMA     1.9 ± 0.1     3.0 ± 0.3 0.001 
Triglycerides (mM)   71.9 ± 8.4   88.4 ± 7.7 NS 
Total cholesterol (mM)   217.7 ± 10.5 207.0 ± 8.0 NS 
HDL (mM)   55.3 ± 2.6   41.9 ± 1.7 <0.0001 
LDL (mM) 148.1 ± 9.4 147.3 ± 6.7 NS 
SBP (mmHg)      111.9 ± 3.7 125.5 ± 3.1 0.01 


















































Figure 12. Omentin levels in lean and overweight/obese individuals. Subjects were 
paired in sib pairs. (A) Lean subjects had higher omentin levels (* P < 0.05) than 
overweight/obese subjects. The latter group had a predominance of overweight over 
obese individuals (14 versus 8 individuals, respectively). (B) Omentin concentrations 
for each subject pair. Note that for most pairs, lean individuals had higher omentin 












































Figure 13. Plasma omentin levels in lean and overweight/obese female individuals. 
Subjects were paired in sib pairs. (A) Female lean subjects had higher plasma 
omentin levels (1.25 ± 0.09 µg/mL, n = 11) than in the overweight/obese group (1.08 
± 0.03 µg/mL, n = 11, P = 0.03, paired Student t-test). (B) Plasma omentin 
concentrations for each subject pair. Note that for most pairs, lean individuals had 











































Figure 14. Plasma omentin concentrations in lean and overweight/obese male 
individuals. Subjects were paired in sib pairs. (A) Plasma omentin levels were not 
significantly different between male lean subjects (1.03 ± 0.03 µg/mL) and 
overweight/obese subjects (1.01 ± 0.03 µg/mL, n = 11, P = 0.39, paired Student t-





















n = 22 n = 22
 Males
Figure 15. Plasma omentin levels in female and male subjects. Plasma omentin levels 
were significantly higher in women (1.16 ± 0.05 µg/mL, n = 22) compared with men 









TABLE 6 – Correlations between log-transformed plasma omentin levels and 
subjects’ clinical and demographic characteristics. The Pearson correlation coefficient 
(r) describes the strength of association between the variables. Prior to regression 
analysis, data were tested for normality of distribution by the Shapiro-Wilk test. In 
consequence, HOMA, triglyceride, and insulin levels were log transformed to obtain 
a normal distribution.    
 
Characteristics r P n 
Age  0.08713 NS 44 
Total cholesterol (mM) 0.01083 NS 42 
Triglycerides (mM) - 0.2161 NS 42 
LDL (mM) - 0.06577 NS 42 
Fasting Insulin (µU/mL) - 0.1806 NS 44 
Fasting Glucose (mM) 0.1630 NS 42 

























































Figure 16. Correlation between log-transformed plasma omentin with BMI and HDL 
levels. The lines of best fit are indicated in each graph. (A) Plasma omentin levels 
were significant negatively correlated with BMI (Pearson correlation coefficient, r = 
−0.39, P = 0.0088, n = 44, 22 women, 22 men). (B) There was observed a significant 
positive correlation between plasma omentin and HDL levels (Pearson correlation 
coefficient, r = 0.41, P = 0.0078, n = 42, 20 women, 22 men). 
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
The discovery of adipocytokines has led to the realization that adipose tissue 
does not only serve as a depot for energy storage, but in fact, also functions as an 
endocrine organ. This represented a fundamental paradigm shift in human nutrition 
and physiology (26-31). 
Adipocytokines, such as adiponectin, leptin and resistin have been previously 
correlated with insulin resistance and obesity (26, 29, 31, 34, 42, 44, 51, 52). It has 
also been shown that omentin increases insulin signal transduction and insulin-
stimulated glucose transport in 3T3-L1 adipocytes and isolated human adipocytes. In 
addition to that, omentin secretion is regulated positively by dexamethasone and 
thiazolidininedione (TZD) compounds (used to enhance insulin sensitivity) in human 
adipose explant cultures. These preliminary data suggest that omentin may play a 
positive role in maintaining insulin sensitivity, possibly improving obesity-related 
insulin resistance. 
As a first step in investigating the role played by omentin in human 
physiology, plasma omentin levels in lean and obese/overweight subjects were 
measured; and the relationships between plasma omentin levels and several metabolic 
indices were investigated. 
These preliminary data showed higher plasma omentin levels in lean versus 
obese/overweight subjects (1.14 ± 0.05 µg/mL vs. 1.04 ± 0.02 µg/mL, P < 0.05, 
paired Student’s t-test). This finding correlates with previous reports of higher plasma 
adiponectin levels in lean compared with obese subjects (36, 42, 46, 49). On the other 
hand, it is well established that plasma leptin and resistin levels are higher in obese 
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than in lean subjects (34, 36, 40, 53). Based on several studies, the approximate 
difference between lean and obese subjects in percentage for adiponectin, leptin, and 
resistin are respectively 35%, 78%, and 25%. Although the difference found for 
omentin was only 10% (figure 12), there are important aspects to consider: (i) the 
different methodologies to measure each adipocytokine used in each study; (ii) the 
group of subjects used in the study. 
First, in this present study, quantitative western blotting was used to measure 
plasma omentin levels, as opposed to standardized, commercially available 
immunoassays kits used to measure adiponectin, leptin and resistin in the other 
investigations. It is well known that quantitative western blotting can be a technically 
challenging assay. Initial experiments (data not shown) evaluated 3 different types of 
anti-omentin antibodies: 2 monoclonal mouse anti-omentin (3G1B3 and 4G2E9) and 
1 polyclonal rabbit anti-omentin (16070) (all human-omentin specific and developed 
at the Division of Endocrinology, Diabetes and Nutrition, UMB). These results 
indicated that anti-omentin antibody 3G1B3 gave the best signal-to-noise ratio and 
was selected for use in the rest of the experiments (data not shown). Also, initial 
experiments indicated that this antibody did not detect human adiponectin in serum 
samples (data not shown). On the other hand, commercially available immunoassays 
are recognizably more accurate and sensitive than quantitative western blotting 
analysis, resulting in less variability among different samples. However, in spite of 
these limitations the differences between obese/overweight and lean subjects were 
significant.  
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A second potential confounding factor was the limitation in obtaining plasma 
samples from a higher number of obese volunteers. Because of the reduced number of 
obese individuals (8 versus 14 overweight), overweight and obese subjects were 
combined in a single group and paired against lean relatives. The main advantage of 
recruiting volunteers from the Amish population of Lancaster County is the ability to 
obtain subjects with a homogeneous life style. However, most of them are more 
physically active than their non-Amish urban counter parts (see introduction for 
details). This suggests the possibility that a comparison between lean and obese 
subjects (with a standard sedentary lifestyle), such as the subjects investigated in 
other adipocytokine studies, may indicate greater variation in omentin levels than 
observed in the Amish. 
Surprisingly, the difference in plasma omentin levels was significant only 
between lean and overweight/obese women (1.25 ± 0.09 µg/mL vs. 1.08 ± 0.03 
µg/mL, P < 0.02, paired Student’s t-test, figure 13). Moreover, plasma omentin levels 
were significantly higher in women than men (1.16 ± 0.05 µg/mL vs. 1.02 ± 0.02 
µg/mL, P < 0.01, Student’s t-test, figure 15). Adiponectin, leptin and resistin levels 
are also about 50% higher in women than in men (29, 36, 37, 38, 40, 42, 46, 49, 50, 
53). The difference for omentin levels between women and men was about 14%. The 
smaller relative difference between omentin and the other adipocytokines in women 
versus men probably derives from the same causes discussed above for the absolute 
plasma levels of omentin.  
On the other hand, there was not difference between lean and 
overweight/obese individuals in the male population (1.03 ± 0.03 µg/mL vs. 1.01 ± 
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0.03 µg/mL, figure 14). These data are consistent with the lack of a significant 
difference in plasma resistin levels between obese and lean males as described by 
Degawa-Yamauchi et al (2003), (53).  
Taken together, these results suggest an effect of sex hormones (estrogen, 
progesterone, and testosterone) on plasma omentin levels. Epidemiological studies 
established that women have a lower risk of cardiovascular diseases than men (see 
introduction for details). If higher omentin levels are associated with this lower risk, 
or are a consequence of some other, more fundamental cause, this will require further 
investigation. Further studies with adipose tissue cultures should clarify this situation. 
Plasma omentin levels showed a significant negative correlation with BMI     
(r = −0.39, P = 0.0088, figure 16A). According to other studies, leptin and resistin are 
positively correlated with BMI, while adiponectin is negatively correlated with BMI 
(34, 36, 38, 39, 40, 42, 45, 46, 47, 53). This result corroborates the hypothesis that 
low omentin levels may be associated with higher risk of metabolic syndrome, 
indicated by the BMI index. Moreover, to further validate the correlation between 
omentin and BMI, a study measuring plasma omentin levels before and after weight 
loss can be conducted. 
In agreement with other studies for adiponectin, leptin and resistin, a 
significant correlation between plasma omentin levels and HOMA (homeostasis 
model assessment of insulin resistance) was not found in this study (34, 36, 40). 
Although HOMA is considered by several authors an imprecise method of assessing 
insulin resistance compared with the hyperinsulinemic euglycemic clamp technique, 
these data suggest that omentin is more tightly linked with degree of obesity than 
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insulin resistance levels. In order to verify more carefully the correlation between 
omentin levels and insulin resistance, a study using hyperinsulinemic euglycemic 
clamp technique could be designed. In this case, the insulin resistance index would be 
more precise, not leaving doubts about the possible correlation between omentin and 
insulin sensitivity.  
In addition, plasma omentin levels were significant positively correlated with 
HDL levels (r = 0.41, P = 0.0078, figure 16B). Negative correlations without 
statistical significance were found between omentin and triglycerides, and LDL (table 
5). The same pattern has been previously found for adiponectin, while the opposite 
was found for leptin and resitin (45, 46, 48). These data show that higher omentin 
levels are associated with a healthy lipid profile, suggesting that omentin may play a 
role in the same anti-atherogenic behavior as adiponectin. 
Interestingly, plasma omentin levels did not have a statistically significant 
correlation with age, total cholesterol, fasting glucose and blood pressure, probably 
due to the absence of significant differences in these factors between the lean and 
overweight/obese subjects, as well as the small sample size. With a higher number of 
female volunteers, it would be interesting to search for a correlation between age and 
plasma omentin levels, because of the natural hormonal variation experienced by 
woman according to age. This might shed light on the hormonal regulation of 
omentin expression. 
Future directions can be drawn from these data. First, omentin's correlation 
with certain metabolic indices is similar to adiponectin, indicating that a higher 
omentin level is seen as a positive factor that may affect obesity and its associated 
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pathologies. Also, in vitro experiments can be designed to investigate synergistic 
effects between the two adipocytokines. In addition, it would be interesting to verify 
the correlations between plasma omentin levels, and adiponectin, leptin, and resistin 
levels. Second, sex hormones influence omentin expression/or secretion as evidenced 
by the higher omentin levels in women than men. Future studies could address this 
question using hormone-stimulated tissue culture models, as other investigators have 
conducted with adiponectin. 
Finally, it is still necessary to study omentin gene expression and secretion in 
lean, overweight, and obese subjects. Since it is not possible to investigate mRNA 
levels in plasma, this study could be developed using surgical biopsies of omental fat 
from lean, overweight, and obese subjects to gain a greater understanding of the 
molecular control of omentin expression and secretion. Consequently, using these 
preliminary data, it should be possible to determine the necessary sample size 
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